Dr. Heidi Noels and Dr. Yvonne Döring receive the W.H. Hauss Award from the DGAF
19-21 April 2018
Dr. Heidi Noels from the Institute for Molecular Cardiovascular Research at RWTH Aachen University together with Dr. Yvonne Döring from the Institute for Prophylaxis and Epidemiology of Circulatory Diseases at LMU Munich together received the DGAF W.H. Hauss Award 2018 from the German Society for Atherosclerosis Research (DGAF) during the 32nd Annual Meeting of the DGAF in Rauischholzhausen, Germany. They were awarded for their publication "Vascular CXCR4 Limits Atherosclerosis by Maintaining Arterial Integrity: Evidence From Mouse and Human Studies." (Circulation. 2017; 136: 388-403). In this work it could be shown that vascular CXCR4 has an atheroprotective function by maintaining the arterial integrity and preserving the endothelial barrier function. In addition, CXCR4 stabilizes a contractile smooth muscle cell phenotype. Targeted enhancement of these CXCR4-mediated protective functions could open up novel therapeutic options in the treatment of atherosclerosis.
The award was sponsored by a long-standing active member of the DGAF, Prof. Dr. Winfried März.
Project area Z
Administrative project
Robert Werner Mertens
MD student
University Hospital RWTH Aachen
Department of Internal Medicine
Project: The role of incretin hormone GLP-2 in septic cardiomyopathy
PI: Michael Lehrke
Robert Werner Mertens
MD student
University Hospital RWTH Aachen
Department of Internal Medicine
Project: The role of incretin hormone GLP-2 in septic cardiomyopathy
PI: Michael Lehrke
Consortium
Mechanisms of Cardiovascular Complications
in Chronic Kidney Disease
The SFB/TRR219 is supported by the German Research Foundation (DFG)
Project-ID 322900939
PhD MD TRR219-associated students
Elias Haj-Yehia
MD student
University Hospital RWTH Aachen
Department of Internal Medicine
Project: The effect Linagliptin and Saxagliptin in acute myocardial infarction
PI: Michael Lehrke
DPP4 inhibitors (including Linagliptin and Saxagliptin among others) are a class of antidiabetic drugs acting by augmentation of the GLP-1 system. GLP-1 is an incretin hormone released after nutritional and inflammatory stimuli leading to glucose dependent insulin secretion. Although similar glucose lowering efficiacy is reached by different DPP4 inhibitors, only Saxagliptin was found to increase heart failure hospitalization in patients with diabetes. This unexpected effect might relate to the metabolism of Saxagliptin.
We compare the DPP4 inhibitors Linagliptin and Saxagliptin and the Saxagliptin metabolite 5-hydroxy-Saxagliptin during acute myocardial infarction in a murine model of left anterior descending artery ligation.